| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1086/367933 |
| P8608 | Fatcat ID | release_nia2g6jnyzeklbzfex6kknt3si |
| P698 | PubMed publication ID | 12594645 |
| P5875 | ResearchGate publication ID | 10892825 |
| P2093 | author name string | Leonard B Johnson | |
| Carol A Kauffman | |||
| P2860 | cites work | A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients | Q28189320 |
| Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever | Q28216366 | ||
| Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis | Q28217179 | ||
| In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi | Q28355507 | ||
| In vitro activities of four novel triazoles against Scedosporium spp | Q28366842 | ||
| International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobia | Q30453797 | ||
| In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa | Q33975945 | ||
| In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum | Q33979873 | ||
| Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis | Q34052582 | ||
| Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy | Q34092362 | ||
| Disseminated phaeohyphomycosis: review of an emerging mycosis | Q34498615 | ||
| Review of the safety and efficacy of voriconazole | Q34544679 | ||
| Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients | Q34553509 | ||
| Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole. | Q38970314 | ||
| Efficacy of voriconazole in treatment of murine pulmonary blastomycosis | Q39476353 | ||
| Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens | Q39652421 | ||
| Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes | Q39652863 | ||
| In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B. | Q42540459 | ||
| Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole | Q43092918 | ||
| Development of azole resistance during fluconazole maintenance therapy for AIDS-associated cryptococcal disease | Q43792499 | ||
| In vitro susceptibility of clinical isolates of Zygomycota to amphotericin B, flucytosine, itraconazole and voriconazole | Q43815766 | ||
| Voriconazole versus liposomal amphotericin B in patients with neutropenia and persistent fever | Q43864045 | ||
| Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis | Q43864353 | ||
| Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study | Q43949805 | ||
| Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients | Q43961537 | ||
| Decisions about voriconazole versus liposomal amphotericin B. | Q43986711 | ||
| Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children | Q43989240 | ||
| Voriconazole versus liposomal amphotericin B for empirical antifungal therapy | Q44010601 | ||
| A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). | Q46555720 | ||
| Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum. | Q54091144 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | voriconazole | Q412236 |
| P304 | page(s) | 630-637 | |
| P577 | publication date | 2003-02-10 | |
| P1433 | published in | Clinical Infectious Diseases | Q5133764 |
| P1476 | title | Voriconazole: a new triazole antifungal agent | |
| P478 | volume | 36 |
| Q64245308 | A Personalized CYP2C19 Phenotype-Guided Dosing Regimen of Voriconazole Using a Population Pharmacokinetic Analysis |
| Q42045887 | A case of gastric zygomycosis in a diabetic patient successfully treated with total gastrectomy. |
| Q34631174 | A case of pseudomembranous colitis after voriconazole therapy. |
| Q34011074 | A five-year survey of dematiaceous fungi in a tropical hospital reveals potential opportunistic species |
| Q35589104 | A rare presentation of zygomycosis (mucormycosis) and review of the literature |
| Q37918556 | Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations |
| Q38942862 | Adverse effects of voriconazole: Over a decade of use. |
| Q46763769 | Aggressive cutaneous squamous cell carcinoma associated with prolonged voriconazole therapy in a renal transplant patient |
| Q42173257 | An integrated approach for identification and target validation of antifungal compounds active against Erg11p |
| Q36724783 | An update on the use of antifungal agents |
| Q43449387 | Anidulafungin: a new therapeutic approach in antifungal therapy. Pharmacology of anidulafungin |
| Q92613683 | Antifungal Drugs Influence Neutrophil Effector Functions |
| Q37798956 | Antifungal Treatment of Small Animal Veterinary Patients |
| Q46666432 | Antifungal activities of diphenyl diselenide alone and in combination with fluconazole or amphotericin B against Candida glabrata |
| Q37159568 | Antifungal agents--clinical pharmacokinetics and drug interactions |
| Q34400255 | Antifungal clinical trials and guidelines: what we know and do not know |
| Q42723597 | Antifungal drugs: predicting clinical efficacy with pharmacodynamics |
| Q36505508 | Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents |
| Q37310029 | Antifungal therapeutic drug monitoring: established and emerging indications |
| Q37421528 | Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: an update |
| Q37763928 | Antifungals to treat Candida albicans |
| Q38202581 | Antimicrobial agents, drug adverse reactions and interactions, and cancer |
| Q40458948 | Aspergillus flavus Keratitis: Experience of a Tertiary Eye Clinic in Turkey. |
| Q36361928 | Aspergillus flavus scleritis: successful treatment with voriconazole and caspofungin |
| Q33854124 | Aspergillus mastoiditis in a patient with systemic lupus erythematosus: a case report |
| Q35966134 | Aspergillus mediastinitis following orthotopic heart transplantation: case report and review of the literature |
| Q34641443 | Aspergillus niger: an unusual cause of invasive pulmonary aspergillosis |
| Q36641985 | Bench-to-bedside review: Candida infections in the intensive care unit |
| Q58806129 | Biguanides enhance antifungal activity against Candida glabrata |
| Q36909333 | CNS pharmacokinetics of antifungal agents |
| Q51631938 | CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects. |
| Q46315494 | Candida Meningitis After Transsphenoidal Surgery: A Single-Institution Case Series and Literature Review. |
| Q51175452 | Candida urinary tract infections--treatment. |
| Q36777855 | Candida urinary tract infections: treatment options |
| Q37106636 | Central nervous system infections by members of the Pseudallescheria boydii species complex in healthy and immunocompromised hosts: epidemiology, clinical characteristics and outcome |
| Q31006560 | Cerebral phaeohyphomycosis caused by Fonsecaea monophora. |
| Q36920608 | Changing epidemiology of rare mould infections: implications for therapy |
| Q35678997 | Changing strategies for the management of invasive fungal infections |
| Q34130445 | Characteristics of pathogenic fungi and antifungal therapy in cystic fibrosis |
| Q35833407 | Choices aplenty: antifungal prophylaxis in hematopoietic stem cell transplant recipients |
| Q41004012 | Cholesterol import by Aspergillus fumigatus and its influence on antifungal potency of sterol biosynthesis inhibitors |
| Q47645128 | Chronic Pulmonary Aspergillosis-Where Are We? and Where Are We Going? |
| Q57036259 | Clinical Pharmacokinetics of Second-Generation Triazoles for the Treatment of Invasive Aspergillosis and Candidiasis |
| Q34505582 | Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America |
| Q37328834 | Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis |
| Q44866472 | Clinical factors associated with fluconazole resistance and short-term survival in patients with Candida bloodstream infection |
| Q36968140 | Clinical pharmacology of antifungal agents in pediatric patients |
| Q42408609 | Clinical significance of azole antifungal drug cross-resistance in Candida glabrata |
| Q37750488 | Clinical utility of voriconazole eye drops in ophthalmic fungal keratitis |
| Q44728020 | Co-administration of caspofungin and cyclosporine to a kidney transplant patient with pulmonary Aspergillus infection |
| Q35964636 | Combination of intracameral and intrastromal voriconazole in the treatment of recalcitrant Acremonium fungal keratitis |
| Q38011807 | Combination therapy of Western drugs and herbal medicines: recent advances in understanding interactions involving metabolism and efflux. |
| Q49908560 | Corneal Collagen Cross-Linking for the Management of Mycotic Keratitis. |
| Q35578433 | Corneal fungal disease in small animals |
| Q41708603 | Correlation of CYP2C19 genotype with plasma voriconazole levels: a preliminary retrospective study in Indians |
| Q37151326 | Current options in antifungal pharmacotherapy. |
| Q30657637 | Curvularia abscess of the brainstem |
| Q39093310 | Cutaneous bacterial species from Lithobates catesbeianus can inhibit pathogenic dermatophytes |
| Q35270872 | Cytotoxicity of voriconazole on cultured human corneal endothelial cells |
| Q37157893 | Defining targets for investigating the pharmacogenomics of adverse drug reactions to antifungal agents |
| Q36738130 | Dematiaceous fungi |
| Q36112211 | Design and Evaluation of Voriconazole Eye Drops for the Treatment of Fungal Keratitis |
| Q36936716 | Design and Evaluation of Voriconazole Loaded Solid Lipid Nanoparticles for Ophthalmic Application |
| Q49558135 | Design, Synthesis and Cytotoxic Evaluation of Novel Chalcone Derivatives Bearing Triazolo[4,3-a]-quinoxaline Moieties as Potent Anticancer Agents with Dual EGFR Kinase and Tubulin Polymerization Inhibitory Effects. |
| Q40638888 | Development and Validation of Voriconazole Concentration by LC-MS-MS: Applied in Clinical Implementation. |
| Q36429699 | Drug interactions during therapy with three major groups of antimicrobial agents |
| Q36283721 | Drug-drug interactions of antifungal agents and implications for patient care |
| Q46386344 | Economic evaluation of voriconazole versus amphotericin B in the treatment of invasive aspergilosis |
| Q36757926 | Effects of a defective endoplasmic reticulum-associated degradation pathway on the stress response, virulence, and antifungal drug susceptibility of the mold pathogen Aspergillus fumigatus |
| Q34142180 | Effects of voriconazole on Cryptococcus neoformans |
| Q44558731 | Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome |
| Q42286250 | Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. |
| Q40164914 | Efficacy of posaconazole in a murine model of central nervous system aspergillosis |
| Q45957532 | Efficacy of voriconazole in Japanese quail (Coturnix japonica) experimentally infected with Aspergillus fumigatus. |
| Q38261282 | Elevated fluoride levels and periostitis in pediatric hematopoietic stem cell transplant recipients receiving long-term voriconazole |
| Q36066009 | Emerging azole antifungals |
| Q80464838 | Endophthalmitis due to Trichosporon beigelii in acute leukemia |
| Q53748960 | Enhanced skin deposition and delivery of voriconazole using ethosomal preparations. |
| Q29616758 | Epidemiology of invasive candidiasis: a persistent public health problem |
| Q42038850 | Eradication of pulmonary aspergillosis in an adolescent patient undergoing three allogeneic stem cell transplantations for acute lymphoblastic leukemia. |
| Q34483712 | Evaluation of Hepatotoxicity with Off-Label Oral-Treatment Doses of Voriconazole for Invasive Fungal Infections |
| Q36130619 | Experience with community-based amphotericin B infusion therapy |
| Q48303818 | Fifty-one cases of fungal arteritis after kidney transplantation: A case report and review of the literature. |
| Q36839698 | Fosamprenavir calcium plus ritonavir for HIV infection |
| Q35387111 | Fungal infections in renal transplant patients |
| Q38252946 | Fungal infections of the skin and nail: new treatment options. |
| Q36616182 | Fungal pneumonia due to molds in patients with hematological malignancies |
| Q45054608 | Fusarium dimerum infection in a stem cell transplant recipient treated successfully with voriconazole. |
| Q44728023 | Fusarium osteomyelitis of the foot in a patient with diabetes mellitus |
| Q92823781 | Genomewide Elucidation of Drug Resistance Mechanisms for Systemically Used Antifungal Drugs Amphotericin B, Caspofungin, and Voriconazole in the Budding Yeast |
| Q35714132 | Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. |
| Q33650105 | Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of Amer |
| Q34212799 | Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the |
| Q35746695 | Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections. |
| Q37904672 | Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics. |
| Q34980027 | Hepatic safety of voriconazole after allogeneic hematopoietic stem cell transplantation. |
| Q36019684 | High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients |
| Q42401237 | High plasma concentration of beta-D-glucan after administration of sizofiran for cervical cancer |
| Q99725688 | Histological Effects of Intravitreal Injection of Antifungal Agents in New Zealand White Rabbits: An Electron Microscopic and Immunohistochemical Study |
| Q47643761 | Histoplasmosis and Blastomycosis in Solid Organ Transplant Recipients |
| Q43247661 | How immunocompromised are short bowel patients receiving home parenteral nutrition? Apropos a case of disseminated Fusarium oxysporum sepsis |
| Q35070838 | Human pharmacogenomic variations and their implications for antifungal efficacy |
| Q57153715 | Human steroid and oxysterol 7α-hydroxylase CYP7B1: substrate specificity, azole binding and misfolding of clinically relevant mutants |
| Q52820816 | In vitro assessment of non-irritant microemulsified voriconazole hydrogel system. |
| Q41091429 | In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp |
| Q51737787 | In vitro susceptibility of a large collection of Candida Strains against fluconazole and voriconazole by using the CLSI disk diffusion assay. |
| Q28304841 | In-vitro activity of miltefosine and voriconazole on clinical isolates of free-living amebas: Balamuthia mandrillaris, Acanthamoeba spp., and Naegleria fowleri |
| Q35622021 | Infections caused by Fusarium species |
| Q64131246 | Interacciones farmacológicas en el paciente crítico. ¿Un factor relevante para usar micafungina? |
| Q47649550 | Interpersonal factors in the Pharmacokinetics and Pharmacodynamics of Voriconazole: Are CYP2C19 genotypes enough for us to make a clinical decision? |
| Q46520649 | Intravenous voriconazole therapy in a preterm infant |
| Q36403666 | Invasive aspergillosis in children with hematologic malignancies |
| Q35616161 | Invasive aspergillosis in patients with hematologic malignancies. |
| Q38066616 | Invasive aspergillosis in the intensive care unit |
| Q37643057 | Invasive fungal infections in the ICU. |
| Q38180287 | Invasive fungal infections in the ICU: how to approach, how to treat. |
| Q37095685 | Invasive pulmonary aspergillosis in patients with COPD: a report of five cases and systematic review of the literature |
| Q33911297 | Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: a case report and review of the literature |
| Q28298468 | Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial) |
| Q45247488 | Long-term voriconazole and skin cancer: is there cause for concern? |
| Q42627710 | Maintenance of therapeutic concentrations of caspofungin after temporary treatment interruption (48 hours) in a child with invasive aspergillosis |
| Q51177304 | Management of candidemia and invasive candidiasis |
| Q37909774 | Management of fungal lung disease in the immunocompromised. |
| Q24633163 | Melanized Fungi in Human Disease |
| Q42291897 | Melanized fungus as an Epidural abscess: A diagnostic and therapeutic challenge |
| Q37738437 | Modern antifungal therapy for neutropenic fever |
| Q40401842 | Modern antifungal therapy for neutropenic fever |
| Q37064440 | Modern management of chronic granulomatous disease |
| Q51002022 | Molecular dynamic modeling of CYP51B in complex with azole inhibitors. |
| Q40235041 | Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients |
| Q37534298 | Mucormycosis in immunochallenged patients |
| Q36172497 | Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring |
| Q41605775 | Multifocal aggressive squamous cell carcinomas induced by prolonged voriconazole therapy: a case report. |
| Q36974048 | Neurologic Adverse Events Associated with Voriconazole Therapy: Report of Two Pediatric Cases |
| Q30912454 | New antifungal agents: voriconazole and caspofungin |
| Q35917388 | New developments in antifungal strategy |
| Q35744330 | Newer antifungal agents |
| Q36491819 | Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations |
| Q42857169 | Novel conformationally restricted triazole derivatives with potent antifungal activity |
| Q37079085 | Oesophageal candidiasis in elderly patients: risk factors, prevention and management |
| Q37786165 | Opportunistic Fungi: A View to the Future |
| Q37726198 | Opportunistic invasive fungal infections: diagnosis & clinical management |
| Q95933989 | Oral absorption of voriconazole is affected by SLCO2B1 c.*396T>C genetic polymorphism in CYP2C19 poor metabolizers |
| Q37979762 | Oral antifungal therapy for chronic rhinosinusitis and its subtypes: a systematic review |
| Q41611462 | Painful periostitis in the setting of chronic voriconazole therapy |
| Q33635247 | Peripheral eosinophilia and eosinophilic colitis during long-term azole therapy for pulmonary aspergillosis |
| Q38880522 | Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections |
| Q37820674 | Pharmacoeconomics of voriconazole in the management of invasive fungal infections |
| Q36520587 | Pharmacokinetic/pharmacodynamic profile of voriconazole |
| Q38681635 | Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients |
| Q33232599 | Pharmacological advances in the treatment of invasive candidiasis |
| Q37641375 | Pharmacology and clinical use of voriconazole |
| Q36764126 | Plasma Voriconazole Estimation by HPLC. |
| Q35152691 | Plasma fluoride level as a predictor of voriconazole-induced periostitis in patients with skeletal pain |
| Q40675074 | Population pharmacokinetic analysis of voriconazole from a pharmacokinetic study with immunocompromised Japanese pediatric subjects |
| Q44334907 | Population pharmacokinetic evaluation with external validation and Bayesian estimator of voriconazole in liver transplant recipients |
| Q80066469 | Posaconazole |
| Q36323256 | Posaconazole: a broad-spectrum triazole antifungal |
| Q36927577 | Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring |
| Q60960914 | Presence of -glycosidically linked oligosaccharides in the cell wall mannan of purified with Benanomicin A |
| Q37327107 | Present situation in the treatment of invasive fungal infection |
| Q34286912 | Primary central nervous system phaeohyphomycosis: a review of 101 cases |
| Q48155956 | Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). |
| Q36667269 | Prothioconazole and prothioconazole-desthio activities against Candida albicans sterol 14-α-demethylase |
| Q45107364 | Pseudoporphyria as a result of voriconazole use: a case report |
| Q37420895 | Quality control limits for voriconazole disk susceptibility tests on Mueller-Hinton agar with glucose and methylene blue |
| Q40383432 | Quantification of voriconazole in plasma by liquid chromatography-tandem mass spectrometry |
| Q35912243 | Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. |
| Q35183728 | Recommendations for the treatment of fungal pneumonias |
| Q34276700 | Resistance to antifungals that target CYP51. |
| Q37055215 | Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent |
| Q42435668 | Risk-adjusted relationship between voriconazole utilization and non-melanoma skin cancer among lung and heart/lung transplant patients |
| Q34402342 | Saccharomyces boulardii induced sepsis: successful therapy with voriconazole after treatment failure with fluconazole |
| Q36271648 | Safety and potential of drug interactions of caspofungin and voriconazole in multimorbid patients. |
| Q37662650 | Safety of triazole antifungal drugs in patients with cancer |
| Q33824506 | Scedosporium apiospermum soft tissue infection successfully treated with voriconazole: potential pitfalls in the transition from intravenous to oral therapy |
| Q44807745 | Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients |
| Q34413393 | Serum voriconazole level variability in patients with hematological malignancies receiving voriconazole therapy |
| Q41868987 | Simultaneous determination of voriconazole and posaconazole concentrations in human plasma by high-performance liquid chromatography. |
| Q38833311 | Sphingolipids as targets for treatment of fungal infections |
| Q43295186 | Stability of extemporaneously prepared voriconazole ophthalmic solution |
| Q46881807 | Standard dosing regimen of liposomal amphotericin B is as effective as a high-loading dose for patients with invasive aspergillosis: AmBiLoad trial |
| Q41010354 | Strategies for antifungal treatment failure in intensive care units |
| Q37827872 | Strategies to manage antifungal drug resistance |
| Q36093075 | Structure-Functional Characterization of Cytochrome P450 Sterol 14α-Demethylase (CYP51B) from Aspergillus fumigatus and Molecular Basis for the Development of Antifungal Drugs |
| Q44634373 | Successful Voriconazole Therapy of Disseminated Fusarium Solani in the Brain of a Neutropenic Cancer Patient |
| Q43115263 | Successful treatment of Aspergillus liver abscesses in a patient with acute monoblastic leukemia using combination antifungal therapy including micafungin as a key drug |
| Q83996843 | Successful use of combination antifungal therapy in the treatment of coccidioides meningitis |
| Q43240160 | Successful use of voriconazole for treatment of Coccidioides meningitis |
| Q44510174 | Successsful voriconazole treatment of disseminated fusarium infection in an immunocompromised patient |
| Q43919713 | Surveillance of perioperative infections after adult living donor liver transplantation |
| Q33592487 | Susceptibility of filamentous fungi to voriconazole tested by two microdilution methods |
| Q93041526 | Synergistic effect of terbinafine and amphotericin B in killing Fonsecaea nubica in vitro and in vivo |
| Q44606392 | Systemic antifungal agents |
| Q46961708 | Systemic antifungals. Pharmacodynamics and pharmacokinetics |
| Q46593127 | The hepatotoxicity of antifungal medications in bone marrow transplant recipients |
| Q40255550 | The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole |
| Q36273788 | The influence of combination use of CYP450 inducers on the pharmacokinetics of voriconazole: a systematic review |
| Q35183734 | The lipid formulations of amphotericin B. |
| Q36608562 | Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole |
| Q37688257 | Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology |
| Q27009221 | Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective |
| Q30981299 | Therapeutic drug monitoring of voriconazole in Japanese patients: analysis based on clinical practice data |
| Q35973543 | Therapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children |
| Q36233517 | Therapy of infections caused by dematiaceous fungi |
| Q44701980 | Therapy of severe fungal infections |
| Q34301534 | Topical voriconazole as a novel treatment for fungal keratitis |
| Q92008666 | Toxicity studies for the use of prodrug of voriconazole in rats |
| Q35901736 | Treatment of invasive Aspergillosis in children with hematologic malignancies |
| Q37255172 | Treatment of invasive candidiasis in immunocompromised pediatric patients |
| Q46670782 | Treatment options for paracoccidioidomycosis and new strategies investigated |
| Q35664186 | Treatment principles for Candida and Cryptococcus |
| Q37945308 | Triazole antifungal agents drug-drug interactions involving hepatic cytochrome P450. |
| Q36521993 | Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazole |
| Q44973763 | Two cases of severe phototoxic reactions related to long-term outpatient treatment with voriconazole |
| Q51110220 | Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing. |
| Q44728017 | Unsuccessful treatment with voriconazole of a brain abscess due to Cladophialophora bantiana |
| Q35782575 | Update in the epidemiology, prophylaxis, and treatment of fungal infections in patients with hematologic disorders. |
| Q37892901 | Update on the optimal use of voriconazole for invasive fungal infections |
| Q38536076 | Update on the treatment of disseminated fusariosis: Focus on voriconazole. |
| Q42071108 | Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by clinical and laboratory standards institute-recommended broth microdilution methods |
| Q41604057 | Use of nebulized amphotericin B in the treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis |
| Q47700700 | Use of systemic antifungals in daily clinical practice in the haematology and oncology setting: results of a prospective observational analysis |
| Q37071133 | Use of terbinafine in rare and refractory mycoses |
| Q42563983 | Visual Hallucinations Associated with High Posaconazole Concentrations in Serum |
| Q36729599 | Voriconazole : a review of its use in the management of invasive fungal infections |
| Q46083230 | Voriconazole for cryptococcal meningitis in children with leukemia or receiving allogeneic hemopoietic stem cell transplant. |
| Q39196770 | Voriconazole for prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplantation |
| Q35166823 | Voriconazole in the management of nosocomial invasive fungal infections |
| Q36342105 | Voriconazole in the treatment of fungal osteomyelitis of the orbit in the immunocompromised host |
| Q37863923 | Voriconazole is effective as secondary antifungal prophylaxis in leukemia patients with prior pulmonary fungal disease: case series and review of literature |
| Q33613685 | Voriconazole pharmacokinetics in liver transplant recipients. |
| Q39932430 | Voriconazole serum concentrations in prophylactically treated acute myelogenous leukaemia patients |
| Q45227047 | Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients |
| Q46826187 | Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes |
| Q37658869 | Voriconazole therapeutic drug monitoring: focus on safety. |
| Q36720809 | Voriconazole-Induced Photosensitivity in Children: A Case Report and Literature Review |
| Q43010151 | Voriconazole-associated salt-losing nephropathy |
| Q37463484 | Voriconazole-induced periostitis in two post-transplant patients |
| Q38582397 | Voriconazole-induced periostitis post transplant: an illustrative review of thoracic computed tomography imaging manifestations |
| Q38885518 | Voriconazole-induced periostitis: a new rheumatic disorder |
| Q55162562 | Voriconazole-induced photocarcinogenesis is promoted by aryl hydrocarbon receptor-dependent COX-2 upregulation. |
| Q41985408 | Voriconazole-induced photosensitivity |
| Q45170996 | Voriconazole-induced retinoid-like photosensitivity in children |
| Q42429532 | Voriconazole-related periostitis presenting on magnetic resonance imaging |
| Q37810091 | Voriconazole: a broad-spectrum triazole for the treatment of invasive fungal infections |
| Q44420165 | What is the role of therapeutic drug monitoring in antifungal therapy? |
| Q37141191 | When primary antifungal therapy fails |
| Q57789682 | and Assessment of FK506 Analogs as Novel Antifungal Drug Candidates |
Search more.